Abstract
Purpose :
A new perimeter is available that does not require a dark room and can be performed binocularly. The purpose of this study was to compare the performance of two perimeters in the central 10 and 24 degrees of the visual field in a cohort of primarily African American glaucoma patients.
Methods :
A prospective study was conducted at the Illinois Eye Institute,Chicago, Illinois. Inclusion criteria included: best corrected visual acuity of 20/40 or better, diagnosis of glaucoma in one or both eyes, refractive error within -8.00 to +3.00 diopter sphere or cylinder up to 2 diopters, and no history of significant non-glaucomatous ocular disease. Perimetry testing of the central 10 and 24 degrees was performed using both the TEMPO/IMOvifa (Topcon Healthcare/CREWT Medical Systems, Tokyo, Japan) AIZE-Rapid program and the Humphrey Field Analyzer (HFA) (Carl Zeis Meditec, Dublin, California) SITA-Fast algorithm. Main outcome measures were mean deviation (MD) and pattern standard deviation (PSD). The correlation was evaluated using linear regression and limits of agreement based on Bland-Altman analysis. A patient preference survey was performed as well.
Results :
Measurements from 67 eyes for the 24-2 and 68 eyes for the 10-2 of 38 glaucoma patients were compared (age range 39-86yrs). Measurements positively correlated between the devices for both the 24-2 and 10-2 tests with Pearson’s r = 0.89, and 0.88 for MD respectively, and 0.88 and 0.96 for PSD respectively (Figure 1). There was a strong linear correlation between devices with R2 = 0.80, 0.77 for MD and PSD in the 24-2 test and R2 = 0.77 and 0.93 for MD and PSD respectively in the 10-2 test (Figure 2). There was less than 1dB offset between devices and limits of agreement fell within + 6dB. Patient survey data revealed a 92.1% preference for TEMPO.
Conclusions :
TEMPO was found to have comparable results to HFA for both 24-2 and 10-2 testing patterns, and a patient preference for TEMPO was identified. These results are unique and valuable as previous studies have not investigated 10-2 testing. While prior studies focused on Caucasian or Asian populations, this study expands to include a new demographic.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.